Home Cart Sign in  
Chemical Structure| 690206-97-4 Chemical Structure| 690206-97-4

Structure of ZM 306416
CAS No.: 690206-97-4

Chemical Structure| 690206-97-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ZM-306416 is an inhibitor of VEGFR (Flk-1 or KDR) and Flt with IC50 of 100 nM and 2 μM. It also shows inhibition activity against Src and Abl with IC50 values of 0.33μM and 1.3μM, respectively.

Synonyms: CB 676475

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ZM 306416

CAS No. :690206-97-4
Formula : C16H13ClFN3O2
M.W : 333.74
SMILES Code : COC1=CC2=NC=NC(NC3=CC=C(Cl)C=C3F)=C2C=C1OC
Synonyms :
CB 676475
MDL No. :MFCD02683969
InChI Key :YHUIUSRCUKUUQA-UHFFFAOYSA-N
Pubchem ID :5329006

Safety of ZM 306416

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P280-P305+P351+P338-P310

Related Pathways of ZM 306416

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • VEGFR1

    VEGFR1, IC50:0.33 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat Brain Capillary Endothelial Cells (RBEC) 0.33 µM Blocked Sema3A-induced paracellular permeability increase in RBEC PMC4298747
SVF cells 25 μM 160 h ZM 306416 inhibits VEGFR-1, thereby inhibiting stalk cell phenotype. PMC5760587
Human iPSC-derived pericytes 10 µM 6, 12, 24 h Validate VEGFA-SMAD3 interactions, found that VEGFR2 inhibitor treatment significantly increased SMAD3 expression PMC11190273

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish Tg(kdrl:GFP) transgenic zebrafish Treatment in water 10 µM 3 hours per day for three consecutive days Validate VEGFA-SMAD3 interactions and their impact on BBB integrity, found that VEGFR2 blocker treatment increased the percentage of pSMAD3+ endothelial cells and pericytes, and impaired vascular integrity PMC11190273

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.00mL

0.60mL

0.30mL

14.98mL

3.00mL

1.50mL

29.96mL

5.99mL

3.00mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories